DECCOQUIN 522 CONCENTRATE

Main information

  • Trade name:
  • DECCOQUIN 522 CONCENTRATE
  • Class:
  • AgChem
  • Medicine domain:
  • Plants
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • DECCOQUIN 522 CONCENTRATE
    Australia
  • Language:
  • English

Therapeutic information

  • Therapeutic area:
  • FUNGICIDE

Other information

Status

  • Source:
  • Australian Pesticides and Veterinary Medicines Authority (APVMA)
  • Authorization status:
  • Archived
  • Authorization number:
  • 30356
  • Last update:
  • 09-08-2016

19-12-2018

Nature's Ultimate recalls Nature's Ultimate - Concentrated Cleaner 1.9L (64 fl. oz)

Nature's Ultimate recalls Nature's Ultimate - Concentrated Cleaner 1.9L (64 fl. oz)

The child-resistant cap on some units of the product may not function as required by the Consumer Chemicals and Containers Regulations, 2001 under the Canada Consumer Product Safety Act.

Health Canada

12-12-2018

Nettoyants Lemieux recalls Concentrated Dishwasher Powder

Nettoyants Lemieux recalls Concentrated Dishwasher Powder

Health Canada has determined that the recalled product does not comply with Canadian packaging and labeling regulations.

Health Canada

6-12-2018

Tris Pharma Issues Voluntary Nationwide Recall of Infants’ Ibuprofen Concentrated Oral Suspension, USP (NSAID) 50 mg per 1.25 mL, Due to Potential Higher Concentrations of Ibuprofen

Tris Pharma Issues Voluntary Nationwide Recall of Infants’ Ibuprofen Concentrated Oral Suspension, USP (NSAID) 50 mg per 1.25 mL, Due to Potential Higher Concentrations of Ibuprofen

Tris Pharma, Inc. has voluntarily recalled three (3) lots of Infants’ Ibuprofen Concentrated Oral Suspension, USP (NSAID) 50 mg per 1.25 mL, to the retail level. The recalled lots of the product have been found to potentially have higher concentrations of ibuprofen.

FDA - U.S. Food and Drug Administration

5-6-2018

FDA warns companies to stop selling dangerous and illegal pure and highly concentrated caffeine products

FDA warns companies to stop selling dangerous and illegal pure and highly concentrated caffeine products

FDA issued warning letters to the parties responsible for liquidcaffeine.com and Dual Health Body and Mind for illegally selling certain highly concentrated caffeine products.

FDA - U.S. Food and Drug Administration

12-4-2018

Cookwell & Company Issues Allergy Alert for Undeclared Soy, Wheat and Fish Allergen in Charred Tomato & Basil Sauce with a “Best By” Date of “10 Nov 18”

Cookwell & Company Issues Allergy Alert for Undeclared Soy, Wheat and Fish Allergen in Charred Tomato & Basil Sauce with a “Best By” Date of “10 Nov 18”

Cookwell & Company Is voluntarily recalling potentially up to 6,522 units of its Four J Charred Tomato & Basil Sauce because it may contain undeclared soy, wheat and fish. People who have an allergy or severe sensitivity to these allergens may run the risk of a serious or life-threatening allergic reaction if they consume this product.

FDA - U.S. Food and Drug Administration

18-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: Concentrate of autologous bone marrow-derived mononuclear cells (BM-MNC)

Scientific recommendation on classification of advanced therapy medicinal products: Concentrate of autologous bone marrow-derived mononuclear cells (BM-MNC)

Scientific recommendation on classification of advanced therapy medicinal products: Concentrate of autologous bone marrow-derived mononuclear cells (BM-MNC)

Europe - EMA - European Medicines Agency

13-12-2018


Overview of comments received on 'Pegylated liposomal doxorubicin hydrochloride concentrate for solution 2 mg/ml product-specific bioequivalence guidance' (EMA/CHMP/800775/2017)

Overview of comments received on 'Pegylated liposomal doxorubicin hydrochloride concentrate for solution 2 mg/ml product-specific bioequivalence guidance' (EMA/CHMP/800775/2017)

Overview of comments received on 'Pegylated liposomal doxorubicin hydrochloride concentrate for solution 2 mg/ml product-specific bioequivalence guidance' (EMA/CHMP/800775/2017)

Europe - EMA - European Medicines Agency

13-12-2018


Pegylated liposomal doxorubicin hydrochloride concentrate for solution 2 mg/ml product-specific bioequivalence guidance

Pegylated liposomal doxorubicin hydrochloride concentrate for solution 2 mg/ml product-specific bioequivalence guidance

Pegylated liposomal doxorubicin hydrochloride concentrate for solution 2 mg/ml product-specific bioequivalence guidance

Europe - EMA - European Medicines Agency

12-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: Autologous concentrated bone marrow

Scientific recommendation on classification of advanced therapy medicinal products: Autologous concentrated bone marrow

Scientific recommendation on classification of advanced therapy medicinal products: Autologous concentrated bone marrow

Europe - EMA - European Medicines Agency

2-10-2018

NexoBrid (MediWound Germany GmbH)

NexoBrid (MediWound Germany GmbH)

NexoBrid (Active substance: Concentrate of proteolytic enzymes enriched in bromelain) - PSUSA - Modification - Commission Decision (2018)6460 of Tue, 02 Oct 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/PSUSA/10028/201712

Europe -DG Health and Food Safety

10-8-2018

Sivextro (Merck Sharp and Dohme B.V.)

Sivextro (Merck Sharp and Dohme B.V.)

Sivextro (Active substance: tedizolid phosphate) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5522 of Fri, 10 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2846/T/28

Europe -DG Health and Food Safety

1-8-2018

Toviaz (Pfizer Europe MA EEIG)

Toviaz (Pfizer Europe MA EEIG)

Toviaz (Active substance: fesoterodine) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5225 of Wed, 01 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/723/T/52

Europe -DG Health and Food Safety

1-8-2018

Eylea (Bayer AG)

Eylea (Bayer AG)

Eylea (Active substance: aflibercept) - Centralised - 2-Monthly update - Commission Decision (2018)5222 of Wed, 01 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2392/II/45

Europe -DG Health and Food Safety

1-8-2018

Thalidomide Celgene (Celgene Europe Limited)

Thalidomide Celgene (Celgene Europe Limited)

Thalidomide Celgene (Active substance: Thalidomide) - PSUSA - Modification - Commission Decision (2018)5227 of Wed, 01 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/PSUSA/2919/201710

Europe -DG Health and Food Safety

1-8-2018

Grastofil (Apotex Europe B.V.)

Grastofil (Apotex Europe B.V.)

Grastofil (Active substance: filgrastim) - Centralised - Yearly update - Commission Decision (2018)5228 of Wed, 01 Aug 2018

Europe -DG Health and Food Safety

1-8-2018

Lyrica (Pfizer Europe MA EEIG)

Lyrica (Pfizer Europe MA EEIG)

Lyrica (Active substance: pregabalin) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5223 of Wed, 01 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/546/T/95

Europe -DG Health and Food Safety

1-8-2018

IBRANCE (Pfizer Europe MA EEIG)

IBRANCE (Pfizer Europe MA EEIG)

IBRANCE (Active substance: palbociclib) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5224 of Wed, 01 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/3853/T/14

Europe -DG Health and Food Safety

1-8-2018

Revatio (Pfizer Europe MA EEIG)

Revatio (Pfizer Europe MA EEIG)

Revatio (Active substance: sildenafil) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5221 of Wed, 01 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/638/T/82

Europe -DG Health and Food Safety

1-8-2018

Nimenrix (Pfizer Europe MA EEIG)

Nimenrix (Pfizer Europe MA EEIG)

Nimenrix (Active substance: Meningococcal group A, C, W-135 and Y conjugate vaccine) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5220 of Wed, 01 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2226/T/80

Europe -DG Health and Food Safety

1-8-2018

Cyanokit (SERB S.A.)

Cyanokit (SERB S.A.)

Cyanokit (Active substance: hydroxocobalamin) - Centralised - Yearly update - Commission Decision (2018)5229 of Wed, 01 Aug 2018

Europe -DG Health and Food Safety

11-7-2018

Coliprotec F4/F18 (Prevtec Microbia GmbH)

Coliprotec F4/F18 (Prevtec Microbia GmbH)

Coliprotec F4/F18 (Active substance: Porcine post-weaning diarrhoea vaccine (live)) - Centralised - Yearly update - Commission Decision (2018)4522 of Wed, 11 Jul 2018

Europe -DG Health and Food Safety

5-7-2018

Scientific guideline:  Draft pegylated liposomal doxorubicin hydrochloride concentrate for solution 2 mg/ml product-specific bioequivalence guidance, draft: consultation open

Scientific guideline: Draft pegylated liposomal doxorubicin hydrochloride concentrate for solution 2 mg/ml product-specific bioequivalence guidance, draft: consultation open

This document provides product-specific guidance on the demonstration of the bioequivalence of pegylated liposomal doxorubicin hydrochloride concentrate for solution 2 mg/ml.

Europe - EMA - European Medicines Agency

21-5-2018

EU/3/07/522 (Best Regulatory Consulting Ltd)

EU/3/07/522 (Best Regulatory Consulting Ltd)

EU/3/07/522 (Active substance: (manganese, dichloro [(4aR, 13aR, 17aR, 21aR)-1, 2, 3, 4, 4a, 5, 6, 12, 13, 13a, 14, 15, 16, 17, 17a, 18, 19, 20, 21, 21a-eicosahydro-11, 7-nitrilo-7H-dibenzo[ b,h] [1,4,7,10] tetraazacycloheptadecine-?N5, ?N13, ?N18, ?N21, ?N22]-)) - Transfer of orphan designation - Commission Decision (2018)3136 of Mon, 21 May 2018 European Medicines Agency (EMA) procedure number: EMA/OD/089/07/T/01

Europe -DG Health and Food Safety

8-3-2018

Vepesid and associated names

Vepesid and associated names

Vepesid and associated names (Active substance: etoposide) - Corrigendum - Commission Decision (2017)4522 of Thu, 08 Mar 2018

Europe -DG Health and Food Safety